These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19546835)

  • 1. Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer.
    Eguchi H; Ishikawa O; Ohigashi H; Takahashi H; Yano M; Nishiyama K; Tomita Y; Uehara R; Takehara A; Nakamura Y; Nakagawa H
    Pancreas; 2009 Oct; 38(7):791-8. PubMed ID: 19546835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.
    Takehara A; Eguchi H; Ohigashi H; Ishikawa O; Kasugai T; Hosokawa M; Katagiri T; Nakamura Y; Nakagawa H
    Cancer Sci; 2006 Nov; 97(11):1191-7. PubMed ID: 16918991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target.
    Legoffic A; Calvo E; Cano C; Folch-Puy E; Barthet M; Delpero JR; Ferrés-Masó M; Dagorn JC; Closa D; Iovanna J
    PLoS One; 2009 Oct; 4(10):e7495. PubMed ID: 19834624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
    Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
    J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
    Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
    Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Lehtinen L; Carpen O; Andersson LC; Seppänen H; Haglund C
    Tumour Biol; 2018 Mar; 40(3):1010428318761494. PubMed ID: 29542402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
    Takahashi H; Yamada D; Asukai K; Wada H; Hasegawa S; Hara H; Shinno N; Ushigome H; Haraguchi N; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Ohue M; Yano M; Sakon M; Ishikawa O
    Pancreatology; 2020 Jul; 20(5):919-928. PubMed ID: 32563596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence.
    Takahashi H; Akita H; Tomokuni A; Kobayashi S; Ohigashi H; Fijiwara Y; Yano M; Sakon M; Ishikawa O
    Ann Surg; 2016 Dec; 264(6):1091-1097. PubMed ID: 27462960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radically resected pancreatic cancer and adjuvant treatment. A review of the literature].
    Drudi F; Tassinari D; Giuliani J; Ridolfi C; Gianni L; Tamburini E; Fantini M; Santelmo C; Barzotti E; Lotti N; Ravaioli A
    Recenti Prog Med; 2013 Feb; 104(2):80-5. PubMed ID: 23535964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. REG4 contributes to the invasiveness of pancreatic cancer by upregulating MMP-7 and MMP-9.
    He XJ; Jiang XT; Ma YY; Xia YJ; Wang HJ; Guan TP; Shao QS; Tao HQ
    Cancer Sci; 2012 Dec; 103(12):2082-91. PubMed ID: 22957785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer.
    Chen Y; Kang M; Lu W; Guo Q; Zhang B; Xie Q; Wu Y
    J Cancer Res Clin Oncol; 2012 Sep; 138(9):1463-74. PubMed ID: 22526154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.
    Cloyd JM; Wang H; Egger ME; Tzeng CD; Prakash LR; Maitra A; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Overman MJ; Koay EJ; Das P; Herman JM; Kim MP; Vauthey JN; Aloia TA; Fleming JB; Lee JE; Katz MHG
    JAMA Surg; 2017 Nov; 152(11):1048-1056. PubMed ID: 28700784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of REG4 confers an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
    He HL; Lee YE; Shiue YL; Lee SW; Lin LC; Chen TJ; Wu TF; Hsing CH; Huang HY; Wang JY; Li CF
    J Surg Oncol; 2014 Dec; 110(8):1002-10. PubMed ID: 25155043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
    Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
    Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
    Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
    World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hTERT-siRNA could potentiate the cytotoxic effect of gemcitabine to pancreatic cancer cells Bxpc-3.
    Tan J; Zhou X; Zhu H
    Exp Clin Transplant; 2012 Aug; 10(4):386-93. PubMed ID: 22757972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
    Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
    Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemoradiation therapy for pancreatic cancer.
    Takahashi H; Akita H; Wada H; Tomokuni A; Asukai K; Takahashi Y; Yanagimoto Y; Matsunaga T; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Yamamoto T; Nakanishi M; Shirayanagi M; Yamasaki T; Ohue M; Yano M; Sakon M; Ishikawa O
    Surgery; 2018 Dec; 164(6):1168-1177. PubMed ID: 30146098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function.
    Tomimaru Y; Eguchi H; Iwagami Y; Akita H; Noda T; Gotoh K; Kobayashi S; Nagano H; Mori M; Doki Y
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):537-545. PubMed ID: 31834436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function.
    Tomimaru Y; Eguchi H; Satoh T; Tomokuni A; Asaoka T; Wada H; Marubashi S; Ogawa K; Takehara T; Mori M; Doki Y; Nagano H
    Jpn J Clin Oncol; 2015 Apr; 45(4):343-8. PubMed ID: 25589454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.